Immune-related adverse events in checkpoint blockade: Observations from human tissue and therapeutic considerations

Checkpoint inhibitors (CPIs) are monoclonal antibodies which, by disrupting interactions of immune checkpoint molecules with their ligands, block regulatory immune signals otherwise exploited by cancers. Despite revolutionary clinical benefits, CPI use is associated with an array of immune-related a...

Descripción completa

Detalles Bibliográficos
Autores principales: Williams, Kristian C., Gault, Abigail, Anderson, Amy E., Stewart, Christopher J., Lamb, Christopher A., Speight, R. Ally, Rajan, Neil, Plummer, Ruth, Pratt, Arthur G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909476/
https://www.ncbi.nlm.nih.gov/pubmed/36776862
http://dx.doi.org/10.3389/fimmu.2023.1122430

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909476/
https://www.ncbi.nlm.nih.gov/pubmed/36776862
http://dx.doi.org/10.3389/fimmu.2023.1122430

Ejemplares similares